A Trial Evaluating the Combination of the Atezolizumab (TECENTRIQ) and Niraparib (ZEJULA) in Patients with Metastatic Bladder Cancer.

Trial Profile

A Trial Evaluating the Combination of the Atezolizumab (TECENTRIQ) and Niraparib (ZEJULA) in Patients with Metastatic Bladder Cancer.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Niraparib (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 28 Feb 2018 New trial record
    • 26 Feb 2018 According to a TESARO media release, this trial will be conducted by Genentech and is expected to begin mid-2018.
    • 26 Feb 2018 According to a TESARO media release, the company announced that it has entered into a clinical collaboration with Genentech (a member of the Roche Group) to evaluate the combination of Atezolizumab and Niraparib in patients with metastatic bladder cancer.The collaboration includes testing this experimental combination in MORPHEUS which is a phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies more rapidly and efficiently.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top